See more : Carson River Ventures Corp. (CRIV.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Mydecine Innovations Group Inc. (MYCOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mydecine Innovations Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Helo Corp. (HLOC) Income Statement Analysis – Financial Results
- Gemina Laboratories Ltd. (GLAB.CN) Income Statement Analysis – Financial Results
- Hygeia Healthcare Holdings Co., Limited (6078.HK) Income Statement Analysis – Financial Results
- Delhivery Limited (DELHIVERY.BO) Income Statement Analysis – Financial Results
- AGTech Holdings Limited (AGTEF) Income Statement Analysis – Financial Results
Mydecine Innovations Group Inc. (MYCOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mydecine.com
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.49K | 58.49K | 125.57K | 207.66K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K | 0.00 |
| Cost of Revenue | 9.88K | 128.86K | 0.00 | 37.37K | 94.05K | 109.82K | 246.58K | 1.77M | 1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.88K | -128.86K | 7.49K | 21.12K | 31.52K | 97.83K | -246.58K | -1.77M | -1.88M | 84.00K | 49.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 36.11% | 25.10% | 47.11% | 0.00% | 0.00% | -2,243.43% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.08M | 3.59M | 3.96M | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.15M | 9.98M | 14.74M | 7.74M | 3.27M | 4.88M | 14.62M | 3.92M | 3.64M | 808.13K | 46.40K | 0.00 |
| Selling & Marketing | 1.15M | 0.00 | 0.00 | 2.33M | 71.51K | 730.22K | 693.83K | 259.75K | 41.10K | 14.00K | 0.00 | 0.00 |
| SG&A | 8.30M | 9.98M | 14.74M | 10.07M | 3.34M | 5.61M | 15.31M | 4.18M | 3.68M | 822.13K | 46.40K | 12.97 |
| Other Expenses | 0.00 | 2.82M | 3.99M | 292.02K | 149.99K | -4.54M | -97.92K | -4.28K | -2.95K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.64M | 16.39M | 22.69M | 11.65M | 3.49M | 5.90M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Cost & Expenses | 19.64M | 16.39M | 22.69M | 11.69M | 3.58M | 6.01M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Interest Income | 0.00 | 911.59 | 205.27 | 24.67 | 0.00 | 18.62K | 0.00 | 0.00 | 75.00 | 7.00 | 102.00 | 44.97 |
| Interest Expense | 1.30M | 911.59K | 205.27K | 182.87K | 68.31K | 69.95K | 6.90K | 47.42K | 107.13K | 30.02K | 32.88K | 0.00 |
| Depreciation & Amortization | 9.88K | 128.86K | 235.18K | 57.08K | 46.39K | 21.76K | 246.58K | 9.00K | 24.56K | 25.05K | 25.70K | 26.58 |
| EBITDA | -9.38M | -15.92M | -23.14M | -11.12M | -3.21M | -5.78M | -15.46M | -4.18M | -3.83M | -1.17M | 1.44K | -14.21 |
| EBITDA Ratio | 0.00% | 0.00% | -304,709.21% | -19,007.40% | -2,555.37% | -2,782.25% | 0.00% | 0.00% | -4,582.18% | -976.67% | 3.14% | 0.00% |
| Operating Income | -9.39M | -16.05M | -23.07M | -11.21M | -3.32M | -5.80M | -15.70M | 4.19M | 3.72M | 1.11M | 24.16K | -40.80 |
| Operating Income Ratio | 0.00% | 0.00% | -307,847.83% | -19,161.62% | -2,642.24% | -2,792.73% | 0.00% | 0.00% | 4,430.54% | 1,320.65% | 49.31% | 0.00% |
| Total Other Income/Expenses | -11.55M | -1.40M | -515.87K | -15.67M | -18.04M | -7.55M | -1.99M | -3.79M | -264.53K | -464.40K | -83.34K | -45.24 |
| Income Before Tax | -20.95M | -17.24M | -23.58M | -26.95M | -3.51M | -13.36M | -17.56M | -7.96M | -4.64M | -1.23M | -107.60K | -86.03 |
| Income Before Tax Ratio | 0.00% | 0.00% | -314,732.56% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| Income Tax Expense | 0.00 | -5.39M | 5.14M | 608.14K | 219.51K | 69.95K | 6.90K | -306.19K | 107.13K | 30.02K | 32.88K | 0.00 |
| Net Income | -20.95M | -11.85M | -28.72M | -27.56M | -3.73M | -13.36M | -17.56M | -7.60M | -4.64M | -1.23M | -107.60K | -86.03 |
| Net Income Ratio | 0.00% | 0.00% | -383,287.92% | -47,114.19% | -2,968.22% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| EPS | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.45 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| EPS Diluted | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| Weighted Avg Shares Out | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.37K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
| Weighted Avg Shares Out (Dil) | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
Mydecine Announces Partnership with LeadGen Labs
Mydecine Innovations says it is well-funded to advance its IP portfolio and expand clinical trial calendar
Mydecine Innovations Group Inc. (MYCOF) CEO Josh Bartch on Q4 2020 Results - Earnings Call Transcript
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Mydecine Announces API-naming structure of Four Lead Candidates and Prepares for Pre-IND
Mydecine Innovations Group Announces Migration to NEO Exchange
Mydecine Innovations Group Provides Update on European Operations
Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Source: https://incomestatements.info
Category: Stock Reports